|
1
|
Gastrointestinal Tumor Study Group.
Prolongation of the disease-free interval in surgically-treated
rectal carcinoma. N Engl J Med. 312:1465–1472. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Douglass HO Jr, Moertel CG, Mayer RJ, et
al: Survival after postoperative combination treatment of rectal
cancer. N Engl J Med. 315:1294–1295. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kapiteijn E, Putter H and van de Velde CJ:
Impact of the introduction and training of total mesorectal
excision on recurrence and survival in rectal cancer in The
Netherlands. Br J Surg. 89:1142–1149. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
National Cancer Institute of Canada
(NCIC). Common toxicity criteria (CTC) grading system (revised
edition). 1994
|
|
5
|
Moertel CG, Fleming TR, Macdonald JS, et
al: Levamisole and fluorouracil for adjuvant therapy of resected
colon carcinoma. N Engl J Med. 322:352–358. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Poon MA, O’Connell MJ, Moertel CG, et al:
Biochemical modulation of fluorouracil: evidence of significant
improvement of survival and quality of life in patients with
advanced colorectal carcinoma. J Clin Oncol. 7:1407–1418.
1989.PubMed/NCBI
|
|
7
|
Radiation Therapy Oncology Group. [cited;
Available from: http://www.rtog.org/].
|
|
8
|
Miller AB, Hoogstraten B, Staquet M, et
al: Reporting results of cancer treatment. Cancer. 47:207–214.
1981. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Histological typing of intestinal tumours.
WHO. Springer; Berlin: 1989
|
|
10
|
TNM classification of malignant tumours.
4th edition. 2nd revision. UICC. Springer; Berlin: 1992
|
|
11
|
Bujko K, Nowacki MP, Nasierowska-Guttmejer
A, et al: Sphincter preservation following preoperative
radiotherapy for rectal cancer: report of a randomised trial
comparing short-term radiotherapy vs. conventionally fractionated
radiochemotherapy. Radiother Oncol. 72:15–24. 2004. View Article : Google Scholar
|
|
12
|
Minsky BD: Preoperative treatment for
upper cT3 N0 rectal tumors: is it required? ASCO Educational Book.
Govindan R and Curzio J: Alexandria, VA: pp. 204–207. 2009
|
|
13
|
Grann A, Minsky BD, Cohen AM, et al:
Preliminary results of preoperative 5-fluorouracil, low-dose
leucovorin and concurrent radiation therapy for clinically
resectable T3 rectal cancer. Dis Colon Rectum. 40:515–522. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Janjan NA, Khoo VS, Abbruzzese J, et al:
Tumor downstaging and sphincter preservation with preoperative
chemoradiation in locally advanced rectal cancer: the M.D. Anderson
Cancer Center experience. Int J Radiat Oncol Biol Phys.
44:1027–1038. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kaminsky-Forrett MC, Conroy T, Luporsi E,
et al: Prognostic implications of downstaging following
preoperative radiation therapy for operable T3–T4 rectal cancer.
Int J Radiat Oncol Biol Phys. 42:935–941. 1998.PubMed/NCBI
|
|
16
|
Minsky BD, Cohen AM, Kemeny N, et al:
Enhancement of radiation-induced downstaging of rectal cancer by
fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol.
10:79–84. 1992.PubMed/NCBI
|
|
17
|
Sauer R, Becker H, Hohenberger W, et al:
Preoperative versus postoperative chemoradiotherapy for rectal
cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bosset JF, Calais G, Mineur L, et al:
Enhanced tumorocidal effect of chemotherapy with preoperative
radiotherapy for rectal cancer: preliminary results – EORTC 22921.
J Clin Oncol. 23:5620–5627. 2005.PubMed/NCBI
|
|
19
|
Gerard J, Azria D, Gourgou-Bourgade S, et
al: Randomized multicenter phase III trial comparing two
neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus
RT50-Capox) in patients (pts) with locally advanced rectal cancer
(LACR): results of the ACCORD 12/0405 PRODIGE 2. J Clin Oncol.
27:S7972009.
|
|
20
|
Aschele C, Pinto S, Cordio G, et al:
Preoperative fluorouracil (FU)-based chemoradiation with and
without weekly oxaliplatin in locally advanced rectal cancer:
pathologic response analysis of the Studio Terapia Adjuvante Retto
(STAR)-01 randomized phase III trial. J Clin Oncol.
27:S8042009.
|
|
21
|
Rodel C, Martus P, Papadoupolos T, et al:
Prognostic significance of tumor regression after preoperative
chemoradiotherapy for rectal cancer. J Clin Oncol. 23:8688–8696.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Valentini V, Coco C, Picciocchi A, et al:
Does downstaging predict improved outcome after preoperative
chemoradiation for extraperitoneal locally advanced rectal cancer?
A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys.
53:664–674. 2002. View Article : Google Scholar
|
|
23
|
Bosset JF, Collette L, Calais G, et al:
Chemotherapy with preoperative radiotherapy in rectal cancer. N
Engl J Med. 355:1114–1123. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kapiteijn E, Marijnen CA, Nagtegaal ID, et
al: Preoperative radiotherapy combined with total mesorectal
excision for resectable rectal cancer. N Engl J Med. 345:638–646.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Quirke P: Training and quality assurance
for rectal cancer: 20 years of data is enough. The Lancet Oncology.
4:695–702. 2003.PubMed/NCBI
|
|
26
|
Peeters KC, Marijnen CA, Nagtegaal ID, et
al: The TME trial after a median follow-up of 6 years: increased
local control but no survival benefit in irradiated patients with
resectable rectal carcinoma. Ann Surg. 246:693–701. 2007.
|
|
27
|
Janjan NA, Abbruzzese J, Pazdur R, et al:
Prognostic implications of response to preoperative infusional
chemoradiation in locally advanced rectal cancer. Radiother Oncol.
51:153–160. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Willett C, Duda D, Boucher Y, et al: Phase
I/II study of neoadjuvant bevacizumab with radiation therapy and
5-fluorouracil in patients with rectal cancer: initial results.
Proc ASCO. 25:S1732007.
|
|
29
|
Arnold D, Hipp M, Liersch T, et al:
Cetuximab, capecitabine and oxaliplatin (Cet-CapOx) with concurrent
radiotherapy (RT) in advanced rectal cancer (RC): results of a
phase I/II trial. Proc ASCO. 25:S1742007.
|
|
30
|
Nogue M, Salud A, Vicente P, et al:
Addition of bevacizumab to induction plus concomitant
capecitabine-oxaliplatin (XELOX) chemoradiotherapy (CRT) in MRI
poor prognosis locally advanced rectal cancer: avacross study. Proc
ASCO. 4100:S1922009.
|
|
31
|
Bosset JF, Pavy JJ, Hamers HP, et al:
Determination of the optimal dose of 5-fluorouracil when combined
with low-dose D,L-leucovorin and irradiation in rectal cancer:
results of three consecutive phase II studies. EORTC Radiotherapy
Group. Eur J Cancer. 29A:1406–1410. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
The Meta-Analysis Group In Cancer.
Toxicity of fluorouracil in patients with advanced colorectal
cancer: effect of administration schedule and prognostic factors. J
Clin Oncol. 16:3537–3541. 1998.PubMed/NCBI
|
